I guess I wasn't the only one who thought that maybe Zale
Over the weekend, reports came out that Zale and Britain's Signet
A deal would make a certain amount of sense. Signet does well in the mid-market U.S. retail jewelry business (through Kay and Jared), but doesn't really compete on either the higher end (where Zale has Bailey Banks & Biddle) or the lower end (where Zale has Piercing Pagoda). And the combination would definitely be a more formidable bricks-and-mortar competitor to other mass-market retailers that also sell jewelry (like Wal-Mart
The deal would also fit in with some of the rumblings that Signet might want to get rid of the underperforming British business and just focus on the U.S. operations. After all, not only has the financial performance there been disappointing, but as a reader emailed to me, the store operations across the pond are a mess as well (at least in a few stores).
And it might be that Signet already has a willing bidder for those operations. Gerald Ratner, who ran Signet prior to referring to some product(s) as "total crap," has gotten back into the jewelry business and supposedly has said that he'd be interested in the British operations if they were for sale; whether he can actually find the capital for it is a separate question.
Since Signet dwarfs Zale in market cap and revenue, I don't see how this is anything but an acquisition by Signet. By the same token, it'll need to tread carefully. Zale is down but not out, and situations like these call for a bit of tact and soft-stepping, lest the target thinks it is simply the recipient of an opportunistic bid.
For more related Foolishness:
Wal-Mart is a Motley Fool Inside Value recommendation.
Fool contributor Stephen Simpson but has no financial interest in any stocks mentioned (that means he's neither long nor short the shares).
More from The Motley Fool
Is Qualcomm's Grip on NXP Semiconductors Getting Any Tighter?
Investors aren't exactly rushing to complete this $38 billion buyout, but Qualcomm still hopes to complete the deal within a few months.
Alnylam Gets Some Welcome News
A trial that had been on clinical hold because of a patient death has been cleared to restart.
Here's Why Under Armour Inc Stock Surged Almost 12% Today
One Wall Street analyst thinks the worst is over for the athletic apparel and footwear company. Keep reading for deeper insight.